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Genetic risk formultiple sclerosis (MS) is thought to involve both common and rare risk alleles. Recent GWAS and subsequentmeta-anal-
ysis have established the critical role of the HLA locus and identiﬁed new common variants associated to MS. These variants have small
odds ratios (ORs) and explain only a fraction of the genetic risk. To expose potentially rare, high-impact alleles, we conducted a GWAS of
68 distantly related cases and 136 controls from a high-risk internal isolate of Finland with increased prevalence and familial occurrence
of MS. The top 27 loci with p < 104 were tested in 711 cases and 1029 controls from Finland, and the top two ﬁndings were validated
in 3859 cases and 9110 controls from more heterogeneous populations. SNP (rs744166) within the STAT3 gene was associated to MS
(p ¼ 2.75 3 1010, OR 0.87, conﬁdence interval 0.83–0.91). The protective haplotype for MS in STAT3 is a risk allele for Crohn disease,
implying that STAT3 represents a shared risk locus for at least two autoimmune diseases. This study also demonstrates the potential of
special isolated populations in search for variants contributing to complex traits.Multiple sclerosis (MS) (MIM #126200) is a complex
inﬂammatory disease of the central nervous system with
presumed autoimmune etiology. Both environmental
and genetic factors are thought to contribute to the devel-
opment of MS,1–3 and the genetic risk factors likely include
both common and rare risk alleles. Recent GWAS and
subsequent meta-analysis have established the critical
role of the HLA locus4–6 and identiﬁed new MS loci:
IL2RA (MIM *147730),7 IL7R (MIM *146661),7–9 CLEC16A
(MIM *611303),7,10–13 CD58 (MIM *153420),11,12,14
TNFRSF1A (MIM *191190),15 IRF8 (MIM *601565),15 and
TYK2 (MIM *176941).12,16,17 These associated variants,
except for TYK2, are common, have small odds ratios
(ORs), and explain only a fraction of the genetic risk.
The population history of Finland and the province of
Southern Ostrobothnia (SO), an internal isolate with
increased prevalence of MS,18–22 is compatible with a
founder effect.22–24 Previous studies in FinnishMS families
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DRB1 [MIM *142857]),25–27 17q22-24,25,28,29 and 5p14-
p12.25,30–32 Therefore, we hypothesized that some variants
predisposing to MS have either become enriched in SO or
can be more easily detected against a homogenous back-
ground with a genome-wide, high-density SNP screen.
We looked for shared alleles enriched in cases, as well as
potential extended homozygous regions and copy number
variations (CNVs) enriched in MS cases.
We included in our GWAS 72 cases with either both
parents from the high-risk isolate or one parent from the
isolate and positive family history of MS and genotyped
them with the Illumina HumanHap300 chip. Extensive
genealogical research revealed that the majority of the
cases could be traced to two large interrelated pedigrees
(see Figure S1 available online). A total of 2206 popula-
tion-based controls were genotyped with either Illumina
HumanHap300 chip or with Illumina HumanHap610-
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success rates, leaving 72 cases and 2196 controls for the
subsequent analyses, and selected only SNPs present on
both Illumina platforms (297,343 SNPs) for analyses.
Gender check was performed with X chromosomal SNPs,
and no discrepancies between the observed and expected
gender were noted. Identity-by-descent (IBD) analysis
was performed to study possible close cryptic relatedness
between individuals and to identify possible samples
with excess relatedness, suggestive of sample contamina-
tion. We then performed identity-by-state (IBS) and multi-
dimensional scaling analyses: four cases were initially
considered as isolate samples clustered outside the isolate
sample set and were excluded from subsequent analyses
(Figure S2). We selected the two closest IBS-matched
controls for each case, and the ﬁnal GWAS set (isolate
GWAS) consisted of 68 cases and 136 controls. The
genomic inﬂation factor suggested no major inﬂation
(l 1.078) and a fairly well-matched case-control set, which
was also conﬁrmed by quantile-quantile plot analysis of
single SNP association results (Figure S3). Because we had
parental birthplace data for both the cases and the
majority of controls (n ¼ 2174), we could further verify
that all cases and 125 of the 136 selected controls had at
least one parent born in Southern Ostrobothnia, and of
these, 64 cases and 90 controls had both parents born in
Southern Ostrobothnia. We have recently shown a correla-
tion between geographical origin of samples (based on
parental birthplace information) and genome-wide SNP
data in the Finnish population.23 Thus, IBS matching of
cases and controls combined with genealogical informa-
tion should minimize the risk of population substructure
in our study set. All patient samples were collected with
informed consent, and the study design and the Finnish
sample collection have been approved by the Helsinki
University Hospital Ethical Committee of Ophthalmology,
Otorhinolaryngology, Neurology and Neurosurgery
(permit 192/E9/02).
Taking advantage of the distant relatedness in the subi-
solate, we conducted homozygosity analyses with
PLINK.33 First we searched for extended regions of homo-
zygosity (ROHs), the signature features of isolated popula-
tions, enriched inMS cases to identify loci that could inﬂu-
ence MS susceptibility in a recessive manner. ROHs with at
least 50 consecutive SNPs and aminimum length of 500 kb
were identiﬁed in each individual. On average, we identi-
ﬁed 149 (standard deviation: 12 in cases, 10 in controls)
ROHs per individual with an average length of 1030 kb
(500 kb–31.3 Mb) in cases and 1018 kb (500 kb–49.6 Mb)
in controls. We then evaluated which overlapping homo-
zygous regions were enriched in cases by permuting the
group (case-control) labels 10,000 times. The analysis
revealed three putative regions with empirical p < 103:
1q42.12 (242 kb, 24 SNPs, p ¼ 3 3 104), 2q24.3 (512
kb, 39 SNPs, p ¼ 8 3 105), and 12q24.33 (573 kb, 48
SNPs, p ¼ 3 3 104) (Table S1 and Figure S4). Although
the cases and controls are matched on the basis of their
genome-wide IBS sharing and are augmented by parental286 The American Journal of Human Genetics 86, 285–291, Februarybirthplace information, the permutation-based approach
is susceptible to population substructure, and obtained
p values should be interpreted with caution. Excess homo-
zygous sharing was observed with the same haplotype for
13% (9 of MS cases) and 7% (10 of controls) for 1q42.12
and 37% (25 of MS cases) and 20% (27 of controls) for
2q24.3. For the 12q24 region, we observed multiple
different haplotypes (Table S1). These regions have not
been previously implicated in MS except for suggestive
linkage in 12q23-24,34 and their putative role in MS
susceptibility requires further validation. Haplotype
sharing outside of the isolate in the population control
samples (n ¼ 2194) was similar to the GWAS internal
isolate control population (frequencies 5.8% for 1q42.12
and 20% for 2q24.3 haplotypes). This indicates that the
homozygous haplotypes have been enriched in the subiso-
late MS cases, but not in the isolate controls, although the
IBD analysis showed the isolate controls to be as related to
each other as the isolate MS cases (Table S2).
The Illumina HumanHap300 platform has relatively
sparse coverage and is void of probes in the most common
CNV regions but could be suitable for detecting rare, large
CNVs, potentially enriched in the internal isolate popula-
tion.We used the QuantiSNP software35 for CNV detection
(GC content correction option, restricted to CNVs with log
Bayesian factor > 10 and length R 3 SNPs) and veriﬁed
these results visually with Bead Studio 3.3. All CNVs in
centromeric regions were excluded. We identiﬁed alto-
gether 106 CNV regions in 68 cases (Table S3); all but 6
of the 106 CNVs have been previously reported. Further-
more, all novel CNVs were found in only one case each.
Hypothesizing that genes mapping next to the 106 CNVs
identiﬁed in cases could belong to a common pathway
involved in MS etiology, we used Ingenuity Pathway Anal-
ysis to search for connecting pathways. One pathway
potentially regulating oligodendrocyte differentiation
and myelin sheet formation36–41 involving NRG3 (MIM
*605533), ERBB4 (MIM *600543), DLG2 (MIM *603583),
UTRN (MIM *128240), and LARGE (MIM *603590) (all
CNVs previously reported) was identiﬁed (Figure S5), but
CNV deletions in these genes were observed to have
similar frequency in MS cases compared to controls with
Fisher’s exact test (ERBB4: 11% of cases and 12% of
controls, p ¼ 0.388; NRG3: 4% of cases and 4% of controls,
p ¼ 0.90; and DLG2: 1% of cases and 0% of controls, p ¼
0.404) when genotyped in an independent set of 703 cases
and 1051 controls with an in-house-developed PCR-based
fragment analysis method.42
Southern Ostrobothnia is an old isolate, and thus the
expected shared haplotypes are of modest length. We
therefore performed single SNP standard c2 allelic associa-
tion analysis with PLINK.33 Because of the limited power,
we analyzed all 27 loci (28 of the 37 initial SNPs) showing
nominal association in the GWAS analysis (p< 104; Table
S4) in a larger independent Finnish sample set of 711 cases
and 1029 controls, of which 83 MS cases and 365 controls
were from the isolate (Table 1). Population-stratiﬁed12, 2010
Table 1. Description of Sample Sets in GWAS and Replication Studies
Study Population Number of MS Cases Number of Controls Genotyping Platform
Southern Ostrobothnia (SO) isolate GWASa 68 136 Illumina HumanHap300 or
Illumina Human610-quad
Finland SO replicationb 83 365 Sequenom iPlex Gold
Finlandc 628 668 Sequenom iPlex Gold
Norwayd 607 816 Sequenom iPlex Gold
Denmarke 628 1074 Sequenom iPlex Gold
Gene MSA Switzerlandf 253 208 Illumina HumanHap300
Gene MSA Netherlandsf 230 232 Illumina HumanHap300
Gene MSA USf 486 431 Illumina HumanHap300
IMSGC UKg 453 2950 Affymetrix 500K
IMSGC USg 342 1679 Affymetrix 500K
BWHg 860 1720 Affymetrix 6.0
Total 4638 10,279
All samples have been diagnosed with clinically definite MS according to either Poser’s or McDonald’s criteria.
a MS samples included in the genome-wide analysis originated from the MS high-risk isolate located on the western coast of Finland (Southern Ostrobothnia, SO)
with ~2-fold prevalence and higher familial clustering of MS compared to other regions of Finland. Most of the cases were distantly related, and no closer than
second-degree relatives were included (Table S2). The cases were genotyped with Illumina HumanHap300 at The Broad Institute of MIT and Harvard. Control
samples (n ¼ 136) were selected by utilizing identical-by-state (IBS)-sharing and parental birthplace information from a pool of population-based controls (total
n ¼ 2206) genotyped either with Illumina HumanHap300-duo chips at the Institute for Molecular Medicine Finland (FIMM) Technology Centre or with Illumina
Human610-quad chips at the Sanger Institute.
b The MS cases have at least one parent born within SO, and anonymous population controls were collected from the Central Hospital of Seinajoki in Southern
Ostrobothnia. The samples were genotyped in the FIMM Technology Centre.
c Finnish MS patients (excluding samples from the SO region) from various regions (Tampere, Helsinki, Kuopio, Oulu) and anonymous population controls
collected from Kuopio and Helsinki University Hospitals. The samples were genotyped in the FIMM Technology Centre.
d Norwegian samples have been described in more detail in Lorentzen et al.54 The samples were genotyped in the FIMM Technology Centre.
e The Danish nationwide study set cases have been diagnosed with clinically definite MS according to the McDonald criteria. The controls are healthy blood
donors and hospital workers residing in the same region as patients. Experimental protocols (KF 01314 009) were approved by the local ethics board, and
informed consent was obtained from all participants. The samples were genotyped in the FIMM Technology Centre.
f Study sample from the Gene MSA consortium is also a part of the recently published meta-analysis15 and is described in detail elsewhere by De Jager et al.15 and
Baranzini et al.46
g Study sample from a recently published meta-analysis is described in detail elsewhere15 and was kindly provided by De Jager et al.15Cochran-Mantel-Haenszel (CMH) association analysis
provided evidence for three SNPs: rs3135338 in the HLA
region (p ¼ 1.6 3 1025), rs744166 in ﬁrst intron of
STAT3 (MIM *102582) in chromosome 17q21.1 (p ¼
0.0012), and rs1364194 in chromosome 16 (p ¼ 0.0047)
(Table S4). The non-HLA SNPs were then analyzed in an
international sample of 3859 MS cases and 9110 controls
from six different populations (Table 1). The combined
evidence for association to STAT3 (rs744166) was signiﬁ-
cant (p ¼ 2.75 3 1010 and OR 0.87 [95% conﬁdence
interval (CI) 0.83–0.91]) (Figure 1; Table S5). The Breslow-
Day analysis of heterogeneity of odds ratios revealed no
signiﬁcant heterogeneity (p ¼ 0.34). When the combined
replication data set was analyzed by logistic regression for
additive, dominant, and recessive models with study set
as a covariate in the analyses, the statistically most signiﬁ-
cant p value was obtained for the additive model (Table
S6). We obtained no additional support for the chromo-
some 16q region.
Evaluation of the STAT3 linkage disequilibrium (LD)
block that contains the associated SNP rs744166 in Hap-
map2 (build 23a) samples43 with Haploview 4.044 showed
that rs744166 non-risk-associated A allele completely tagsThe Americathe most common haplotype in Southern Utah residents
of European descent (CEU) (56%), Han Chinese from Bei-
jing (CHB 65%), and Tokyo Japanese (JPT 57%), but the
G allele is present on four different haplotypes (Table S7).
In the Yoruban population from Nigeria (YRI), the A allele
is present on four different haplotype backgrounds, and
the most common A haplotype in CEU, CHB, and JPT pop-
ulations has the frequency of 7% in the YRI population.
We speculate that this notable enrichment of a single
haplotype in non-African populations might suggest posi-
tive selection of the putative MS protective haplotype
outside Africa, although this locus did not reach genome-
wide signiﬁcance in an analysis of signs of recent positive
selection.45 The rs744166 A allele also shows changes in
frequency distribution in the Human Genome Diversity
Panel (Figure S6).45 The LD block carrying the haplotype
is 54 kb in length in the CEU population and contains
the beginning of STAT3 and its immediate promoter region
(Figure 2).
We tagged the haplotypes with three SNPs (rs744166,
rs6503695, and rs957970) with Haploview 4.0 tagging
option. These SNPs were genotyped in the Finnish sample
set, and the data for the same SNPs were available fromn Journal of Human Genetics 86, 285–291, February 12, 2010 287
Figure 1. Population-Specific Associa-
tion for the STAT3 rs744166 A Allele
The rs744166 A allele that tags a putative
MS protective haplotype associated to MS
and shows consistent reduced risk in all
studied populations with available geno-
types. The results are presented here by
study set. Each line represents one study
set showing the name of the set, A allele
frequencies for cases and controls, ORs,
p value for association, andgraphic illustra-
tion of the odds ratio (square, size relative
to study set size) with the 95% conﬁdence
intervals for the odds ratio (thin lines).four other populations from a recent meta-analysis.7,15,46
We phased the haplotypes with PLINK and performed
a CMH analysis with populations as clusters. We could
deﬁne both a putative predisposing haplotype (30.9% in
MS, 27.1% in controls, OR 1.18, 95% CI 1.11–1.27) with
CMH p¼ 1.293 106 and a tentative protective haplotype
(55.0% MS, 58.7% controls, OR 0.86, 95% CI 0.81–0.91)
(Figure 1) with CMH combined p ¼ 1.19 3 106 (Table 2;
Tables S7 and S8). The Breslow-Day test revealed no signif-
icant heterogeneity of odds ratios (p ¼ 0.271 and p ¼
0.301, respectively). Further studies, including resequenc-Figure 2. Description of the Associated LD Region in STAT3
The associated SNP and haplotypes are in a 54 kb LD block covering the beginning and
The associated rs744166 SNP is marked with a red arrow, and the other two SNPs, rs6503
analysis are marked with yellow arrows. The SNP marked with the blue arrow (rs22931
suggestively associated to MS in a previous meta-analysis.15
288 The American Journal of Human Genetics 86, 285–291, February 12, 2010ing, will be needed to identify the
true affecting variants segregating in
one or both of these haplotypes.STAT3 codes for a transcription factor that is involved in
multiple pathways and functions, including the Jak-STAT
pathway, neuron axonal guidance, apoptosis, activation
of immune responses, and Th17 cell differentiation.47
Interestingly, the A allele of rs744166 tagging the MS-
protective haplotype is associated with Crohn disease,48
and mutations in STAT3 are known to cause hyperimmu-
noglobulin E recurrent infection syndrome (HIES [MIM
#147060]),49,50 a rare autosomal-dominant disorder char-
acterized by elevated immunoglobulin E levels and inﬂam-
mation. Additionally, mouse studies have shown thatimmediate 50 region of the STAT3 gene.
695 and rs957970, used in the haplotype
52) was listed among the 100 top SNPs
Table 2. Summary of the 54 kb STAT3 Haplotype Data Showing
One Putative Predisposing and One Putative Protective Haplotype
Haplotype
Frequency
MS
(n ¼ 3255)
Frequency
Control
(n ¼ 8133) P Value OR 95% CI
CGGa 0.309 0.271 1.29 3 106 1.18 (1.11–1.27)
TAAb 0.550 0.587 1.19 3 106 0.86 (0.81–0.91)
TGG 0.082 0.080 0.439 1.06 (0.94–1.17)
CGA 0.057 0.059 0.591 0.98 (0.85–1.10)
The haplotypes were constructed with SNPs rs6503695, rs744166, and
rs957970 and phased with PLINK. Only phased haplotypes with posterior
probability of 1 were included in the analysis. Each haplotype was analyzed
separately and showed no evidence for heterogeneity of odds ratios between
populations in the Breslow-Day test, which allowed us to combine the haplo-
type results with CMH. The analysis included a total of 3255 MS cases and
8133 controls from Finnish, BWH, IMSGC UK, IMSGC US, Gene MSA US,
Gene MSA CH, and Gene MSA NL sample sets. The results for individual
populations are provided in Table S5.
a The predisposing haplotype CGG is significantly overrepresented in the
MS cases.
b The protective haplotype TAA is significantly underrepresented in the
MS cases.targeted deletion of Stat3 in CD4þ T cells prevents the
development of experimental autoimmune encephalomy-
elitis (EAE), the rodent model of MS,51 and that Treg-
speciﬁc ablation of Stat3 resulted in the development of a
fatal intestinal inﬂammation due to unstrained TH17
response.52 Recent meta-analysis of GWAS in MS listed
STAT3 as one of the genes with a suggestive role in at least
two autoimmune disorders15 but failed to replicate the
initial STAT3 association. The failure to replicate the initial
association was probably due to selecting the most signiﬁ-
cantly associated regional SNP (rs2293152), which resides
just outside of the rs744166 containing LD region and
has only limited LD with the rs744166 (r2 0.35 in
HapMap2 CEU population), for the replication analysis
(Figure 2). These observations support a wider role for
STAT3 in autoimmunity and adds this gene to the growing
list of MS-susceptibility genes with validated or substantial
evidence for association in at least two inﬂammatory
diseases.48–50 All of these together suggest a signiﬁcant
role of this locus in immune system and autoimmune
disease pathogenesis.
Most of the currently validated (IL2RA, IL7R, CD58,
CLEC16A, IRF8, TNFRSF1A, TYK2)7,9,12–17,53 and suggested
(C7 [MIM *217070], CD6 [MIM *186720], IL12A [MIM
*161560], OLIG3 [MIM *609323]–TNFAIP3 [MIM
*191163], PTGER4 [MIM *601586], RGS1 [MIM
*600323])15,30 non-HLAMS susceptibility loci have known
functions in the immune system and particularly in Tcells.
Although their independent ORs are modest, their
combined effect might be larger, and a large-scale interna-
tional study would be required to estimate their combined
effect toward disease predisposition. The present study
demonstrates the power of the founder population study
design to complement large-scale GWAS in identifying
genes and pathways of general signiﬁcance, not only rare
high-impact alleles.The AmericaSupplemental Data
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